



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ş

In re Application of:

Amnon PELED et al

Serial No.:

10/649,873

Filed:

28 August 2003

For:

Novel Chemokine Binding Peptides

Capable of Modulating the

Biological Activity of Chemokines

Examiner:

Bruce D. Hissong

Group Art Unit: 1646

Attorney Docket: 26732

Mail Stop Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL ELECTION RESPONSE

Sir:

This is further the response to the United States Patent and Trademark Office Restriction Action mailed June 6, 2006, a response which was filed on August 6, 2006, and in which Applicants elected Group V, namely Claims 56-58, drawn to a method of treating disease using family 2 peptidic chemokine modulators.

Applicants notes that the election of Group V was made according to the wording related to this group in the above-mentioned Restriction Action, namely, a method of treating disease using family 2 peptidic chemokine modulators.

However, Applicants have now been made aware that claims 56-58 of the instant application actually refer to a method of treating disease using peptidic chemokine modulators as defined in Table 1, whereas it is claims 53-55 that relate to treating disease using family 2 peptidic chemokine modulators.

In the above mentioned Restriction Action, Claims 53-55 were apparently erroneously included within Group IV, drawn to a method of treating disease using 2

family 1 peptidic chemokine modulators, when in fact, they relate to treating disease using family 2 peptidic chemokine modulators.

Applicants wish to maintain their election of the invention based on the wording of Group V claims, namely, a method of treating disease using family 2 peptidic chemokine modulators.

Applicants therefore respectfully request that Claims 53-55, drawn to a method of treating disease using family 2 peptidic chemokine modulators, be examined.

Respectfully submitted,

Martin Moynihan,

Registration No. 40,338

Date: September 13, 2006